pharmaceutical · input
Active pharmaceutical ingredient for Tylenol/paracetamol — the world's most widely used analgesic. China produces ~35% of global APAP API directly; India ~26%; but China supplies >75% of PAP (the upstream precursor), making effective Chinese supply chain exposure much higher.
4
Source countries
6
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on acetaminophen (apap) api somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| CNChina | 35% |
| INIndia | 30% |
| EUEuropean Union | 15% |
| USUnited States | 2% |
Who makes it
6 companies produce acetaminophen (apap) api.
Claims to be the world's largest integrated APAP producer; ~52,000–53,000 tonnes/year capacity; backward-integrated into para-aminophenol production; exports to 65+ countries. Key player in Indian API export growth.
World's largest single-site APAP (acetaminophen) API manufacturer; ~40,000–50,000 tonnes/year capacity; produces ~35% of Chinese APAP output; FDA DMF filed 2011. Also produces para-aminophenol (PAP) as an upstream integrated producer.
Major Indian APAP and ibuprofen API and finished dosage form manufacturer; ~12% global APAP market share; 5 dedicated API plants; expanded capacity Q3 2024. Supplies global branded and generic OTC companies.
Chinese pharmaceutical and chemical company (SZSE: 002216, HQ Hengshui, Hebei; ~RMB 5B revenue); major producer of acetaminophen (paracetamol) API and its key precursor para-aminophenol (PAP). Hebei Jiheng is one of China's largest single-facility APAP producers and a major PAP manufacturer — controlling the full supply chain from aniline (derived from benzene/toluene/xylene petrochemicals) through PAP to APAP. Hebei province's chemical industry cluster (Hengshui, Shijiazhuang) includes multiple facilities producing the aniline, nitrobenzene, and para-aminophenol intermediates that feed APAP synthesis globally. Hebei Jiheng's PAP production capability makes it a critical upstream supplier not just for its own APAP but for Indian APAP producers (Farmson, Granules) who depend on Chinese PAP when domestic Indian PAP capacity is insufficient.
Operates the only APAP API manufacturing facility in North America (Raleigh, NC). Emerged from its second Chapter 11 bankruptcy in November 2023; opioid liabilities drove both bankruptcies, not APAP operations. Only "Western" acetaminophen API producer at commercial scale.
